Brainstorm Cell Therapeutics (BCLI) Misses Q2 EPS by 11c

Brainstorm Cell Therapeutics (NASDAQ: BCLI) reported Q2 EPS of ($0.27), $0.11 worse than the analyst estimate of ($0.16).

For earnings history and earnings-related data on Brainstorm Cell Therapeutics (BCLI) click here.

You May Also Be Interested In

• Micron offers Taiwan workers up to 68-month bonuses as strike threat looms
• Brinker Int'l (EAT) PT Lowered to $240 at DA Davidson Ahead of Analyst Day
• DA Davidson Reiterates Buy Rating on Oracle (ORCL) Following Q1 Print